IMPACT OF INTRAVENOUS ESOMEPRAZOLE ON CRP, IL-8, AND IL-16 LEVELS IN YOUNG ATHLETES WITH DUODENAL ULCER

Abstract

Objective: To explore the impact of intravenous esomeprazole on CRP, IL-8, and IL-16 levels in young athletes with duodenal ulcers. Methods: This study involved 173 young athletes diagnosed with duodenal ulcers at our hospital from January 2017 to January 2022. Participants were randomly assigned to a control group (n=86) and a study group (n=87). We compared gastrointestinal symptom scores, oxidative stress indices, immune function, and inflammatory markers before and after treatment between the two groups. Results: Post-treatment, the study group reported significantly lower scores for abdominal pain, bloating, acid reflux, and belching compared to the control group (P<0.05). Additionally, oxidative stress improved in the study group, as indicated by lower malondialdehyde levels and higher levels of glutathione peroxidase and superoxide dismutase (P<0.05). Immune function was also enhanced in the study group, with higher levels of CD3+, CD4+, and CD4+/CD8+ ratios (P<0.05). Importantly, the levels of inflammatory markers CRP, IL-8, and IL-16 were significantly reduced in the study group compared to the control group (P<0.05). Conclusions: Intravenous esomeprazole treatment effectively alleviates gastrointestinal symptoms, enhances oxidative stress response, boosts immune function, and suppresses inflammatory markers in young athletes with duodenal ulcers. These findings support the clinical use of esomeprazole for managing duodenal ulcers in this specific population, suggesting a significant benefit in enhancing recovery and maintaining athletic performance during gastrointestinal disturbances.